SAN FRANCISCO — I’ve been ducking in and out of breakout sessions at the J.P. Morgan Healthcare Conference. Here’s what I’ve heard and learned so far:

The Celgene era at JPM fizzled out without much fanfare. Bristol-Myers Squibb and Celgene shared the stage early Monday morning for a fireside chat, but Bristol CEO Dr. Giovanni Caforio did most of the talking. As you’d expect, he’s extremely bullish about the outlook for the combined companies. Caforio filled his biopharma buzzword bingo card.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy